GenVoy™ Platform
GenVoy Research Use Only (RUO) lipid nanoparticle reagents, and a proprietary LNP library designed to accelerate genetic medicine development.
GenVoy Lipid Nanoparticles

The GenVoy Delivery Platform comprises off-the-shelf RUO reagents such as GenVoy-ILM™ that can be used to prepare RNA-LNP for discovery and proof-of-concept studies, and a proprietary LNP Library designed to take your genetic medicine to the clinic.


GenVoy Delivery Platform Diagram

The Genetic Medicine Challenge

Genetic medicine requires efficient delivery of the nucleic acid-based drug to the target cell to affect gene expression. Two clinically-validated genetic medicine technologies are:


Viral Vectors
Viral Vector

Delivers gene using a modified virus


High immune response

Potential genomic insertion

Limited gene size

Potential anti-vector immunity

Cell culture Required

Lipid Nanoparticles
Lipid Nanoparticle Illustration

Delivers gene using an LNP


Low immune response

No genomic insertion

Increased gene size

Lower potential anti-vector immunity

Cell-free manufacturing

What Are Lipid Nanoparticles?

Lipid Nanoparticles (LNP) are the most advanced delivery systems used in non-viral genetic medicines.

The lipid nanoparticle is designed to protect the nucleic acid payload, assist with cell uptake and release the payload into the cytosol.



Learn More About Lipid Nanoparticles


Read more about a case study describing development of a mRNA-LNP Gene Therapy using lipid nanoparticles.



mRNA Case Study

Screen Shot 2020-12-02 at 3.12.57 PM

Accelerate Genetic Medicine Discovery and Proof-of-Concept


GenVoy-ILM is an off-the-shelf Research Use Only lipid nanoparticle reagent designed for use with the NanoAssemblr platform for simple, rapid production of RNA-LNP.


GenVoy-ILM is based on clinical LNP and can be used as a representative formulation for proof-of-concept studies, or to benchmark new LNP under development.






GenVoy-ILM mRNA-LNP showed similar biophysical and biological behaviour when compared to mRNA-LNP containing the ionizable cationic lipid, MC3, which is used in the FDA approved RNA-LNP Onpattro®.

GenVoy ILM Epo1 GenVoy Graph Epo 2

Develop Genetic Medicines from Discovery to Approved Product

Vaccines, Gene Therapy and Cell Therapy demand different characteristics from Lipid Nanoparticles. For example, mRNA-LNP vaccines are administered by intramuscular injection and are designed to elicit an immune response. In contrast, mRNA-LNP are administered by intravenous infusion and formulations that provoke an immune response can affect therapeutic efficacy.


Precision Nanosystems’ LNP library comprises proprietary lipids and LNP formulations that have been designed for specific applications. Partner with Precision to leverage our LNP library and expertise to develop a bespoke lipid nanoparticle formulation for your genetic medicine

PNI Custom Lipid ICL

Custom RNA-LNP formulations elicited a strong immune response in an influenza challenge study.


“Of particular note is LM03PE which had IgG levels of almost 108 ng/mL. We've never seen antibody levels this high.” 

Anna Blakney


Anna Blakney, PhD

 Imperial College London

Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.